Table 1 Baseline characteristics of patients
Variables | All (n = 49) |
|---|---|
Age (years), mean ± SD | 65.3 ± 8.9 |
Sex, n (%) | Â |
 Male | 40 (81.6%) |
 Female | 9 (18.4%) |
Pathological type, n (%) | Â |
 Squamous cell carcinoma | 34 (69.4%) |
 Adenocarcinoma | 15 (30.6%) |
Clinical stage, n (%) | Â |
 III | 22 (44.9%) |
 IV | 26 (53.1%) |
 NA | 1 (2.0%) |
EGFR mutations, n (%) | Â |
 Positive | 3 (6.1%) |
 Negative | 16 (32.7) |
 NA | 30 (61.2%) |
PD-L1 (TPS), n (%) | Â |
 < 1% | 2 (4.1%) |
 1-49% | 2 (4.1%) |
 ≥ 50% | 5 (10.2%) |
 NA | 40 (81.6%) |
Previous treatment, n (%) | Â |
 Surgery | 2 (4.1%) |
 Surgery plus chemotherapy/targeted therapy | 2 (4.1%) |
 Surgery plus radiotherapy | 1 (2.0%) |
 Radiotherapy plus chemotherapy/target therapy | 2 (4.1%) |
 Without prior treatment | 28 (57.1%) |
Previous medications, n (%) | Â |
 Pemetrexed | 11 (22.4%) |
 Cisplatin | 10 (20.4%) |
 Carboplatin | 7 (14.3%) |
 Gefitinib | 5 (10.2%) |
 Bevacizumab | 4 (8.2%) |
 Gemcitabine | 3 (6.1%) |
 Osimertinib | 3 (6.1%) |
 Paclitaxel | 3 (6.1%) |
 Endostar | 3 (6.1%) |
 Toripalimab | 2 (4.1%) |
 Nedaplatin | 2 (4.1%) |
 Anlotinib | 2 (4.1%) |
 Docetaxel | 2 (4.1%) |
 Sintilimab | 1 (2.0%) |
 Pembrolizumab | 1 (2.0%) |
 Nivolumab | 1 (2.0%) |
 Paclitaxel liposome | 1 (2.0%) |
 Vinorelbine | 1 (2.0%) |